Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition

This article was originally published in PharmAsia News

Executive Summary

Takeda's acquisition of Millennium for $8.8 billion will extend the Japanese drug maker's presence in oncology and help stem the loss of revenues as key drugs go generic. Takeda announced plans to acquire the Cambridge, Mass.-based biotech April 10 for $25 per share, a 53 percent premium over the April 9 closing price

You may also be interested in...



Stockwatch: Valeant Attempts To Divert Attention

A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect.

Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup

TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines

Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup

TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines

Related Content

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel